Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors November 10, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development November 4, 2025
Myrio Therapeutics, University of Pennsylvania, and NYU Langone Health to develop next gen solid tumor T cell immunotherapeutics November 4, 2025
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
Updated Rezatapopt Monotherapy Interim Data Announced From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation October 29, 2025
Takeda enters a license and collaboration agreement with Innovent Biologics for IBI363 and IBI343 October 29, 2025
FDA grants non-transferrable voucher for daraxonrasib (RMC-6236) under the Commissioner’s National Priority Voucher (CNPV) pilot program October 29, 2025
Preliminary Data from Ongoing Ph 1/2a Dose Escalation Trial of VS-7375 in Patients with KRAS G12D Mutant Solid Tumors Announced October 29, 2025
Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
CTA Authorization and Initiation of Ph 0/1 Clinical Trial for TGW211 for the Treatment of HER2+ Tumors announced October 21, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 15, 2025
Positive feedback from MHRA provides alignment on the preclinical, manufacturing, clinical & regulatory pathway for ZI-MA4-1 and supports planned CTA submission October 15, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 8, 2025
Initiation of Ph 1/2 study of AVZO-103 in patients with advanced solid tumors announced October 8, 2025
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates October 7, 2025
FDA clears IND application for CDH17-targeting ADC SIM0609 for the treatment of advanced solid tumors October 7, 2025
